GRIFFITH-February 17, 2026 - Compounds Australia (Griffith University), Australia’s national compound management facility, and the  Structural Genomics Consortium (SGC) are excited to announce a new partnership to enable access to high-quality chemical probes to accelerate early drug discovery research. Through this partnership, the SGC’s Donated Chemical Probes (DCP) library is now part of the open access compound collection of Compounds Australia. 

The DCP program, led by SGC at the Goethe University in Frankfurt (SGC-Frankfurt), is an open-science initiative that provides the research community with free, high-quality, well-characterized small molecule probes. These compounds, donated by major pharmaceutical companies and academic labs around the world, target various proteins to advance early drug discovery. Through Compounds Australia, the DCP library can now be accessed in flexible assay-ready formats, enabling med-high throughput screening of the powerful DCP collection.

Compounds Australia is Australia’s national compound management facility housed within the Institute for Biomedicine and Glycomics at Griffith University. Operating under a flexible, open-access policy, the facility plays a critical role in advancing drug discovery, providing international researchers access to high-value compound libraries as well as the specialist expertise and infrastructure required to screen those libraries in high throughput. 

Developed in cooperation with pharmaceutical companies including AbbVie, Bayer, Boehringer Ingelheim, Janssen, MSD, Pfizer, and Takeda, probes  included in the DCP library must meet high standards for potency, selectivity, and cellular on-target activity. Each probe comes with comprehensive characterization data and, where possible, a matching control compound. The collection covers a wide range of targets, including kinases, GPCRs, and ion channels.

Dr Nyssa Drinkwater, Manager of Compounds Australia, said “We’re thrilled to be working with the Structural Genomics Consortium and to add their Donated Chemical Probes to Compounds Australia’s Open Access Collection. With this partnership, our goal is to further accelerate drug discovery through collaboration and resource sharing to meet global health needs”.

“Through our partnership with Compounds Australia, we are expanding access to the DCP collection and simplifying its use for researchers, particularly across the Asia–Pacific region,” said Claudia Tredup, DCP Program Lead at SGC-Frankfurt. “By lowering barriers to access, this collaboration strengthens open science, supports data reproducibility, and enables researchers worldwide to explore biology with confidence.”

About Compounds Australia

Compounds Australia, housed within Griffith University’s Institute for Biomedicine and Glycomics in Queensland, provides critical sample management and logistics services across the drug discovery pipeline. The facility stores and manages a range of open- and closed- access compound collections, plates those collections into flexible assay-ready formats, and distributes them to research organisations around the world.

Compounds Australia acknowledges support provided from the Australian Cancer Research Foundation (ACRF), the Queensland Government, and Therapeutic Innovation Australia (National Collaborative Research Infrastructure Strategy, Australian Government).

About the Structural Genomics Consortium

The Structural Genomics Consortium is a global public-private partnership that seeks to accelerate drug discovery by fostering collaboration among a large network of scientists in academia and industry and making all research outputs openly available to the scientific community. The current SGC research sites are located at Goethe University in Frankfurt, Karolinska Institute, McGill University, UCL, the University of North Carolina, Chapel Hill, the University Health Network (UHN) and Unicamp, Brazil.